Published in Proc Natl Acad Sci U S A on July 07, 2010
Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer (2013) 1.72
Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog (2014) 1.51
Endocytosis and cancer. Cold Spring Harb Perspect Biol (2013) 1.40
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci U S A (2013) 1.06
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A (2013) 1.05
Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies. Proc Natl Acad Sci U S A (2013) 1.04
AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve. Sci Signal (2013) 1.03
Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem (2011) 1.00
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol (2012) 1.00
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. J Mol Biol (2012) 0.91
Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel (2011) 0.91
Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov (2012) 0.90
Back to the future: recombinant polyclonal antibody therapeutics. Curr Opin Chem Eng (2013) 0.86
Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene (2010) 0.86
Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. MAbs (2014) 0.85
Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc Natl Acad Sci U S A (2016) 0.85
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget (2015) 0.84
The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells. MAbs (2014) 0.83
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci U S A (2013) 0.82
Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy. BMC Syst Biol (2014) 0.82
Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers. Mol Cancer Ther (2013) 0.81
Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS One (2014) 0.81
Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab. Pharmaceuticals (Basel) (2012) 0.81
Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain. Sci Rep (2015) 0.79
Green fluorescent protein nanopolygons as monodisperse supramolecular assemblies of functional proteins with defined valency. Nat Commun (2015) 0.78
Molecular dynamics simulations of transitions for ECD epidermal growth factor receptors show key differences between human and drosophila forms of the receptors. Proteins (2013) 0.78
High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface. MAbs (2014) 0.78
Synthetic and natural consensus design for engineering charge within an affibody targeting epidermal growth factor receptor. Biotechnol Bioeng (2016) 0.77
Oligoclonal antibodies to target the ErbB family. Expert Opin Biol Ther (2015) 0.77
A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering. Chem Biol (2015) 0.77
Vascular endothelial growth factor (VEGF) and platelet (PF-4) factor 4 inputs modulate human microvascular endothelial signaling in a three-dimensional matrix migration context. Mol Cell Proteomics (2013) 0.77
Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy. Int J Nanomedicine (2015) 0.77
A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2. J Cell Mol Med (2016) 0.77
Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells. BMC Cancer (2012) 0.76
Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunol Res (2011) 0.76
Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor. MAbs (2014) 0.76
In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. Sci Rep (2017) 0.75
New antibody to stop tumor angiogenesis and lymphatic spread by blocking receptor partnering. Cancer Cell (2010) 0.75
The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget (2016) 0.75
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. Mol Pharm (2017) 0.75
p38 signaling and receptor recycling events in a microfluidic endothelial cell adhesion assay. PLoS One (2013) 0.75
Folliculin Interacts with Rab35 to Regulate EGF-Induced EGFR Degradation. Front Pharmacol (2017) 0.75
ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells. Oncotarget (2017) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis (1999) 45.01
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res (2003) 6.43
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64
Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts. Cell (1981) 5.59
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 4.73
Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics (2005) 4.33
Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane. Nature (1984) 4.27
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell (2003) 4.23
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A (2007) 3.63
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene (2004) 3.27
Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res (2003) 2.90
Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer (2001) 2.69
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem (1989) 2.46
Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J Cell Biol (1988) 2.31
Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J Biol Chem (1985) 2.22
Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated "MAP" kinase. Proc Natl Acad Sci U S A (1991) 2.11
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol (2002) 1.98
Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst (2003) 1.83
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A (2009) 1.71
Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusions. Biophys J (2005) 1.70
Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res (2010) 1.59
Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem (2005) 1.50
The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer (2001) 1.46
c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem Biophys Res Commun (1995) 1.44
Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol (2004) 1.43
EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci (2007) 1.40
Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase. J Biol Chem (1992) 1.39
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol (2009) 1.24
Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res (2006) 1.22
Manual validation of peptide sequence and sites of tyrosine phosphorylation from MS/MS spectra. Methods Mol Biol (2009) 1.16
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res (2005) 1.16
Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab (2009) 1.08
Cycloheximide production by Streptomyces griseus: alleviation of end-product inhibition by dialysis-extraction fermentation. Antimicrob Agents Chemother (1975) 1.07
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther (2008) 1.06
Intracellular receptor/ligand sorting based on endosomal retention components. Biotechnol Bioeng (1996) 1.04
Controlling receptor/ligand trafficking: effects of cellular and molecular properties on endosomal sorting. Ann Biomed Eng (1997) 1.02
Engineering dynamics of growth factors and other therapeutic ligands. Biotechnol Bioeng (1996) 0.80
Causal protein-signaling networks derived from multiparameter single-cell data. Science (2005) 34.28
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol (2002) 8.37
Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc Natl Acad Sci U S A (2006) 7.48
Isolating and engineering human antibodies using yeast surface display. Nat Protoc (2006) 5.02
Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A (2007) 4.80
A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science (2005) 4.75
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Physicochemical modelling of cell signalling pathways. Nat Cell Biol (2006) 4.34
Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics (2005) 4.33
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell (2008) 3.88
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A (2007) 3.63
The response of human epithelial cells to TNF involves an inducible autocrine cascade. Cell (2006) 3.57
Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol (2011) 3.52
Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol (2009) 3.50
Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol (2003) 3.34
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene (2004) 3.27
The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res (2003) 3.18
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol (2006) 3.01
Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Mol Syst Biol (2009) 2.98
14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature (2007) 2.98
Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol (2007) 2.92
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol (2003) 2.85
Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem (2003) 2.77
The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol (2007) 2.74
Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat Methods (2008) 2.68
A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell (2008) 2.65
Modeling a snap-action, variable-delay switch controlling extrinsic cell death. PLoS Biol (2008) 2.63
Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov (2013) 2.59
Mechanotransduction through growth-factor shedding into the extracellular space. Nature (2004) 2.48
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J (2002) 2.42
Co-regulation of cell adhesion by nanoscale RGD organization and mechanical stimulus. J Cell Sci (2002) 2.42
Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys (2004) 2.41
A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates. Nat Methods (2005) 2.39
Cutting to the chase: calpain proteases in cell motility. Trends Cell Biol (2002) 2.38
Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol (2007) 2.38
Oncogenic EGFR signaling networks in glioma. Sci Signal (2009) 2.38
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J (2006) 2.23
Cancer systems biology: a network modeling perspective. Carcinogenesis (2009) 2.22
Logic-based models for the analysis of cell signaling networks. Biochemistry (2010) 2.21
A compendium of signals and responses triggered by prodeath and prosurvival cytokines. Mol Cell Proteomics (2005) 2.20
Common effector processing mediates cell-specific responses to stimuli. Nature (2007) 2.20
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J (2004) 2.20
Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods (2010) 2.20
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J (2002) 2.17
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal (2010) 2.16
Hsp90 recognizes a common surface on client kinases. J Biol Chem (2006) 2.12
Sloppy models, parameter uncertainty, and the role of experimental design. Mol Biosyst (2010) 2.12
Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat Biotechnol (2002) 2.09
Computational model for cell migration in three-dimensional matrices. Biophys J (2005) 2.09
Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem (2002) 2.01
Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci (2011) 2.00
Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci U S A (2011) 2.00
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta (2007) 1.97
Bayesian network approach to cell signaling pathway modeling. Sci STKE (2002) 1.96
Microfluidic shear devices for quantitative analysis of cell adhesion. Anal Chem (2004) 1.95
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal (2013) 1.92
Global network analysis of phenotypic effects: protein networks and toxicity modulation in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2004) 1.90
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell (2011) 1.89
Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res (2003) 1.87
Stochastic kinetics of intracellular huntingtin aggregate formation. Nat Chem Biol (2006) 1.81
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Transforming Boolean models to continuous models: methodology and application to T-cell receptor signaling. BMC Syst Biol (2009) 1.78
Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics (2010) 1.77
Stimulus design for model selection and validation in cell signaling. PLoS Comput Biol (2008) 1.75
Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. PLoS Comput Biol (2006) 1.74
A biological approach to computational models of proteomic networks. Curr Opin Chem Biol (2006) 1.73
Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev (2004) 1.73
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A (2009) 1.71
Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusions. Biophys J (2005) 1.70
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res (2006) 1.69
Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Comput Biol (2009) 1.69
Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med (2007) 1.69
Temporal dynamics of tyrosine phosphorylation in insulin signaling. Diabetes (2006) 1.68
Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66
Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol (2008) 1.64
SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell (2003) 1.63
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A (2004) 1.62
A high-throughput quantitative multiplex kinase assay for monitoring information flow in signaling networks: application to sepsis-apoptosis. Mol Cell Proteomics (2003) 1.61
Microarchitecture of three-dimensional scaffolds influences cell migration behavior via junction interactions. Biophys J (2008) 1.61
Phosphoproteomic analysis of rat liver by high capacity IMAC and LC-MS/MS. J Proteome Res (2006) 1.61
Cue-signal-response analysis of TNF-induced apoptosis by partial least squares regression of dynamic multivariate data. J Comput Biol (2004) 1.61
Phosphoproteomic approaches to elucidate cellular signaling networks. Curr Opin Biotechnol (2006) 1.60
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60
CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms. BMC Syst Biol (2012) 1.60
Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure (2013) 1.59
Collecting and organizing systematic sets of protein data. Nat Rev Mol Cell Biol (2006) 1.58
Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol Cell Biol (2009) 1.56
Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. Mol Cell (2011) 1.55